Novartis eyes Rhapsido’s broader use on positive urticaria data drop
Novartis' Rhapsido (remibrutinib) showed positive results in a late-stage study for chronic induced urticaria (CIndU), potentially expanding its label. The drug demonstrated rapid and sustained symptom improvements across three CIndU subtypes. Novartis plans regulatory submissions for these new indications, aiming to increase Rhapsido's addressable patient population. Analysts expect Rhapsido to reach $5bn in sales by 2032, according to GlobalData.
How this was made
The 30-second read
Why it matters
The Phase III RemIND study shows durable responses across three chronic induced urticaria subtypes, supporting label expansion and significant revenue upside.
Market read
Positive trial data could drive a near‑term stock rally and long‑term valuation uplift for Novartis.
What to watch
Potential competition from other BTK inhibitors and reimbursement challenges.
Background
Novartis' Rhapsido is already approved for chronic spontaneous urticaria and symptomatic dermographism in the US.
Ticker impact
Novartis reported positive Phase III data for Rhapsido in chronic induced urticaria, indicating potential label expansion.
likely upward pressure as investors price in expanded indication and sales potential
Phase III data is a material catalyst; analysts expect the drug to become a blockbuster, which typically lifts the stock.
Market effects
strengthens the biotech/dermatology sector as a new label expansion opportunity.
beneficial for European and Asian markets where the drug is already approved.
adds a potential $5 bn revenue stream to Novartis, influencing global pharma valuations.
Counterpoint
If regulatory hurdles delay approval, the stock may not rally as expected.
Key entities
- companyNovartis
Swiss pharmaceutical giant developing Rhapsido.
- drugRhapsido (remibrutinib)
BTK inhibitor being evaluated for chronic induced urticaria.




